Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Biofrontera Inc (BFRI)

Biofrontera Inc (BFRI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,827
  • Shares Outstanding, K 7,749
  • Annual Sales, $ 34,070 K
  • Annual Income, $ -20,130 K
  • EBIT $ -19 M
  • EBITDA $ -18 M
  • 60-Month Beta 0.38
  • Price/Sales 0.23
  • Price/Cash Flow N/A
  • Price/Book 1.19

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 0.02
  • Number of Estimates 1
  • High Estimate 0.02
  • Low Estimate 0.02
  • Prior Year -2.33
  • Growth Rate Est. (year over year) +100.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8500 +25.88%
on 11/29/24
1.2539 -14.67%
on 12/11/24
+0.0500 (+4.90%)
since 11/26/24
3-Month
0.6513 +64.29%
on 11/18/24
2.2200 -51.80%
on 10/31/24
-0.1900 (-15.08%)
since 09/26/24
52-Week
0.6100 +75.41%
on 02/08/24
3.9000 -72.56%
on 01/04/24
-1.9500 (-64.57%)
since 12/26/23

Most Recent Stories

More News
Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market

BFRI : 1.0700 (+5.94%)
BFRIW : 0.0851 (-29.08%)
Biofrontera Inc. to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

WOBURN, MA / ACCESSWIRE / December 3, 2024 / Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic...

BFRI : 1.0700 (+5.94%)
Biofrontera Inc. Completes $4.2 Million Private Placement of Senior Secured Convertible Note

Biofrontera completes a $4.2 million secured convertible note private placement to support operations and growth initiatives.Quiver AI SummaryBiofrontera Inc. has announced the completion of a $4.2 million...

BFRI : 1.0700 (+5.94%)
Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note

BFRI : 1.0700 (+5.94%)
BFRIW : 0.0851 (-29.08%)
Biofrontera Inc. Reports Third Quarter 2024 Financial Results Amid Hurricane Impact and Positive Product Developments

Biofrontera reported Q3 2024 revenues of $9 million, affected by Hurricane Milton, with notable Ameluz sales growth and FDA approval.Quiver AI SummaryBiofrontera Inc. reported total revenues of $9.0 million...

BFRI : 1.0700 (+5.94%)
Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update

BFRI : 1.0700 (+5.94%)
BFRIW : 0.0851 (-29.08%)
Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

BFRI : 1.0700 (+5.94%)
BFRIW : 0.0851 (-29.08%)
Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

BFRI : 1.0700 (+5.94%)
BFRIW : 0.0851 (-29.08%)
FDA Approves Use of Up To Three Tubes of Biofrontera Inc.’s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment

BFRI : 1.0700 (+5.94%)
BFRIW : 0.0851 (-29.08%)
Global Laser Therapy Devices Billion Dollar Market Thriving on Growing Demand

Palm Beach, FL – October 4, 2022 – FinancialNewsMedia.com News Commentary –  The laser therapy market has been having a very health growth trend in recent years and is expected to continue through...

PIXY : 6.53 (-14.30%)
EW : 75.92 (+0.72%)
BFRI : 1.0700 (+5.94%)
LITE : 85.69 (+1.60%)
CUTR : 0.3189 (-2.42%)

Business Summary

Biofrontera Inc. is a biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on the fields of photodynamic therapy and topical antibiotics. The Company's licensed products focus on the treatment of actinic keratoses,...

See More

Key Turning Points

3rd Resistance Point 1.2105
2nd Resistance Point 1.1543
1st Resistance Point 1.1122
Last Price 1.0700
1st Support Level 1.0139
2nd Support Level 0.9577
3rd Support Level 0.9156

See More

52-Week High 3.9000
Fibonacci 61.8% 2.6432
Fibonacci 50% 2.2550
Fibonacci 38.2% 1.8668
Last Price 1.0700
52-Week Low 0.6100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar